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It is postulated that peptides derived from the N-terminal region of Annexin A1, a
glucocorticoid-regulated 37-kDa protein, could act as biomimetics of the parent protein.
However, recent evidence, amongst which the ability to interact with distinct receptors
other then that described for Annexin A1, suggest that these peptides might fulﬁll other
functions at variance to those reported for the parent protein. Here we tested the ability of
peptide Ac2-26 to induce chemotaxis of human neutrophils, showing that this peptide can
elicit responses comparable to those produced by the canonical activator formyl-Met-Leu-
Phe (or FMLP). However, whilst disruption of the chemical gradient abolished the FMLP
response, addition of peptide Ac2-26 in the top well of the chemotaxis chamber did not
affect (10μM) or augmented (at 30μM) the neutrophil locomotion to the bottom well, as
elicited by 10μMpeptide Ac2-26. Intriguingly, the sole addition of peptide Ac2-26 in the top
wells produced a marked migration of neutrophils. A similar behavior was observed when
human primary monocytes were used. Thus, peptide Ac2-26 is a genuine chemokinetic
agent toward human blood leukocytes. Neutralization strategies indicated that engage-
ment of either the GPCR termed FPR1 or its cognate receptor FPR2/ALX was sufﬁcient to
sustain peptide Ac2-26 induced neutrophil migration. Similarly, application of pharmacolog-
ical inhibitors showed that cell locomotion to peptide Ac2-26 wasmediated primarily by the
ERK, but not the JNK and p38 pathways. In conclusion, we report here novel in vitro prop-
erties for peptide Ac2-26, promoting neutrophil and monocyte chemokinesis; a process
that may contribute to accelerate the resolution phase of inﬂammation.We postulate that
the generation of Annexin A1 N-terminal peptides at the site of inﬂammation may expedite
the egress of migrated leukocytes thus promoting the return to homeostasis.
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INTRODUCTION
Annexin A1 (AnxA1) is a glucocorticoid-regulated 37-kDa pro-
tein that exerts important actions on fundamental processes in
inﬂammation. Highly abundant in myeloid cells, AnxA1 is rapidly
mobilized upon cell activation (non-genomic externalization) or
subsequent to de novo synthesis (genomic activation, e.g., after
glucocorticoid treatment or pro-inﬂammatory cytokine applica-
tion; Perretti and D’Acquisto, 2009). Once on the cell surface the
protein is exposed to extracellular ﬂuids and the in the presence
of calcium undergoes structural re-organization, consequent to
interaction with phospholipids via the core region of the protein
(∼280 amino acid long), which leads to the exposure of the N-
terminal region (∼50 amino acid long; Gerke et al., 2005). This
conformational change is thought to lead to the interaction of the
AnxA1 N-terminus with speciﬁc receptors (Hu et al., 2008). It is
worth recalling here that both human recombinantAnxA1 and the
peptide Ac2-26 exert anti-inﬂammatory and pro-resolving effects
in a variety of experimental models (Perretti and Dalli, 2009).
Moreover, AnxA1 null mice are viable and do not have an appre-
ciable phenotype unless challenged with inﬂammatory stimuli
whereby a stronger and often prolonged reaction is then observed
(Yang et al., 2004; Damazo et al., 2006; Babbin et al., 2008).
In addition to representing the pharmacophore of the pro-
tein affording interaction with counter-ligands, the N-terminus
is also a highly regulated region. It can undergo phosphorylation
on speciﬁc Tyrosine or Serine sites, a pre-requisite for secretion
in certain cell types, or can be cleaved by serine proteases (Solito
et al., 2006; Vong et al., 2007; D’Acquisto et al., 2008). In fact, both
elastase and proteinase 3 have been shown to cleave at speciﬁc
sites within the AnxA1 N-terminal region (Rescher et al., 2006;
Vong et al., 2007) and it is plausible that AnxA1 can be a substrate
for many other proteases. Cleavage of this protein has also been
reported in human inﬂammatory samples including bronchoalve-
olar lavage ﬂuids (Tsao et al., 1998) and blister exudates (Perretti
et al., 1999) suggesting that this process is not an in vitro artifact
but of biological signiﬁcance.
Gerke and colleagues published a break-through study show-
ing that peptides derived from the AnxA1 N-terminus activate
the formyl peptide receptor type 1 (FPR1; Walther et al., 2000).
Subsequently, we showed that full-length AnxA1 can bind and
activate a related receptor termedFPR2/ALX (the lipoxinA4 recep-
tor). This interaction was of physiological relevance since a direct
association between AnxA1 and FPR2/ALX could be shown in
human and mouse activated neutrophils (Perretti et al., 2002).
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Subsequent observations indicated that peptide Ac2-26 activated
all three of the human formyl peptide receptors (Ernst et al., 2004).
Parallel studies from our group showed that whilst peptide Ac2-
26 could bind both FPR1 and FPR2/ALX, the full-length protein
displayed speciﬁc binding only toward FPR2/ALX (Hayhoe et al.,
2006).
It is believed that AnxA1 cleavage can represent a catabolic
event, terminating the “AnxA1 mediated anti-inﬂammatory tone”
(Vong et al., 2007). This hypothesis is backed by the observation
that a cleavage-resistant species of the protein afforded higher
potency in inﬂammatory settings (Pederzoli-Ribeil et al., 2010).
In addition to this, however, it is also possible that AnxA1 cleav-
age could release N-terminal derived sequences that would then
interact with FPR1 eliciting chemotactic responses. This could be
particularly true outside the vasculature were inﬂammatory exu-
dates rich in serine proteases can cleave AnxA1 generating such
peptides.
To address this hypothesis in the present study we assessed (i)
the chemotactic response of human neutrophils (PMN) elicited by
peptide Ac2-26, (ii) the involvement of FPR1 and/or FPR2/ALX in
the observed effects, and (iii) the intracellular pathways engaged
by this peptide.
MATERIALS AND METHODS
NEUTROPHIL AND MONOCYTE ISOLATION
Experiments using healthy volunteers were approved by the local
research ethics committee (P/00/029 East London and The City
Local Research Ethics Committee 1). Informed written consent
was provided according to the Declaration of Helsinki. Blood
was collected into 3.2% sodium citrate and diluted 1:1 in RPMI-
1640 before separation through a double-density gradient using
Histopaque 10771 and 11191 (Sigma-Aldrich, Poole, UK). After
centrifugation at 1340 rpm for 30minpolymorphonuclear (PMN)
and mononuclear cells were collected from lower and upper layers
respectively. Contaminating erythrocytes in the PMN cell suspen-
sion were removed by hypotonic lysis. Cells were ﬁnally washed
and resuspended in RPMI-1640. Monocytes were isolated from
the mononuclear cell suspension by immunomagnetic positive
selection using the EasySep® Human CD14 Positive Selection Kit
(STEMCELL Technologies, Grenoble, France).
CHEMOTAXIS ASSAY
For neutrophil chemotaxis, cells were resuspended at a concen-
tration of 4× 106 cells/ml in RPMI-1640 containing 0.1% BSA.
The assay was performed using 3-μm pore size ChemoTx™ 96
well plates (Neuro Probe Inc., Gaithersburg, USA) by adding
chemotactic stimuli to the bottom wells, and placing 25μl of cell
suspension on top of the ﬁlter. Plates were incubated for 90min
at 37˚C with 5% CO2. After this period ﬁlters were washed with
PBS and plates centrifuged at 1200 rpm for 30 s. Migrated cells
were analyzed by taking 20-μl from the bottomwells and incubat-
ing withAlamar Blue (Invitrogen Ltd. Paisley,UK) and comparing
with a standard curve constructedwith known cell numbers. Plates
were read after 3 h in a ﬂuorescence spectrophotometer at EX560-
EM5 90 nm. For monocyte chemotaxis, the assay was performed
following the same protocol outlined above incubating cells for
120min to allow migration.
In some cases, compounds (see below) were added to freshly
prepared neutrophils for 10min at 37˚C prior to cell addition to
the top well of the chemotactic plates. Anti-FPR1 or anti-FPR2
antibodies were handled in a similar manner.
PHARMACOLOGICAL TOOLS
PeptideAc2-26 (Ac-AMVSEFLKQAWFIENEEQEYVQTVK;Tocris,
Bristol, UK) or FMLP (Sigma-Aldrich, Dorset, UK) were used as
chemoattractants. In initial experiments, also serum amyloid pro-
tein A (SAA; Peprotech, London, UK) was used, since it induces
chemotaxis via FPR2 (He et al., 2003; Ye et al., 2009; Dufton et al.,
2010). Anti-FPR1 or anti-FPR2 monoclonal antibodies (10μg/ml
ﬁnal concentration in either case)were obtained fromR&DSystem
(Abingdon, UK) or Genovac (Brussels, Belgium), respectively).
Inhibitors of mitogen-activated phosphokinase were tested to
learn about the signaling pathway(s) activated by peptide Ac2-26
in these experimental settings. The compounds PD98059 (ERK
inhibitor; Maiti et al., 2008), SB203580 (p38 inhibitor; Maiti et al.,
2008), and SP600125 (JNK Inhibitor – SP600125; Tokuda et al.,
2003) were obtained from Cell Signaling Technologies (Hertford-
shire, UK) and used in the concentration range of 3–30μM as
based on published data (Gallicchio et al., 2009). In selected exper-
iments the ERK inhibitor (10μM) was tested against peptide
Ac2-26 validating blockade of phosphor-ERK accumulation by
Western blotting using a described methodology (Hayhoe et al.,
2006).
STATISTICS
Results are presented as Mean± SEM of n experiments per-
formed in triplicate or quadruplicate. Statistical differences were
determined by analysis-of-variance followed by Dunnet’s or
Bonferroni’s post hoc tests, taking a P-value less than 0.05 as
signiﬁcant.
RESULTS
In initial experiments we tested the effect of peptide Ac2-26 on
human PMN chemotaxis in comparison to the FPR1 agonist
FMLP and the FPR2/ALX agonist SAA. Figure 1 demonstrates
FIGURE 1 | Peptide Ac2-26 provokes migration of human PMN:
comparison to FMLP and SAA. Neutrophils isolated from peripheral blood
of healthy volunteers were resuspended at 4×106 cells/ml and chemotaxis
to peptide Ac2-26 (1–30μM), SAA (1–30μM), or FMLP (1–100 nM) was
assessed over a 90-min period. Results are ±SEM from three to four cell
preparations (**P <0.01, ***P <0.001 vs. PBS group).
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FIGURE 2 | Peptide Ac2-26, but not FMLP, induces PMN chemokinesis.
Peripheral blood neutrophils were incubated with either (A) peptide Ac2-26
(1–30μM) or PBS prior to loading on to 96 well ChemoTx™ plate where the
bottom wells were either loaded with peptide Ac2–26 (10μM) or (B) FMLP
(0.01–1μM) prior to loading on to a chemotaxis plate in the presence of
1 nM FMLP. (C) Neutrophils were incubated with peptide Ac2-26 (1–30μM)
prior to loading on to the chemotaxis plate. Results are ±SEM from three to
four cell preparations [(A,B) *P <0.05 vs. stimulus alone (dose 0 group);
(C) *P <0.05 vs. PBS].
that peptide Ac2-26 can elicit a chemotactic response in the same
order as FMLP, with a near maximal effect at 10μM,which corre-
sponds to 3μg/ml ﬁnal concentration. The positive control FMLP
induced a marked response between 1 and 100 nM concentration
range, and similarly SAA, applied in the bottom well of the cham-
ber at 1–30μM range (Figure 1). Thus, peptide Ac2-26 causes
PMN chemotaxis to a comparable level as produced by FMLP
or SAA.
FIGURE 3 | Both FPR1 and FPR2/ALX mediate peptide Ac2-26 induced
PMN migration. (A) Peripheral blood neutrophils were pre-incubated for
5min at RT with anti-FPR1, FPR2/ALX, or an Isotype control antibody, prior
to loading on to a 96 well ChemoTx™ plate in the presence of 10μM
peptide Ac2-26. Chemotaxis was evaluated after a 90-min incubation at
37˚C and 5% CO2. Results are ±SEM from three distinct cell preparations
(*P <0.05 vs. isotype control). (B) Ac2-26 (10μM) was added to peripheral
blood neutrophils in the presence of absence of PD98059 (ERK inhibitor;
10μM) for 5min prior to protein extraction and assessment of phospho-
and total ERK isoforms, as well as beta-actin. Blots are representative of
triplicate analyses conducted with two distinct neutrophil preparations.
Next we tested whether peptide Ac2-26 elicited genuine PMN
chemotaxis or a chemokinetic response. To this end, we used
10μM peptide Ac2-26 as the chemoattractant concentration, and
added in the topwells, vehicle,orAc2-26 from1 to 30μM.Figure 2
illustrates these results, where Ac2-26 provoked ∼4-fold increase
in PMN migration above control wells, and this effect was not
modiﬁed by adding 1μM Ac2-26 in the top well. However, when
10 or 30μM peptide Ac2-26 were added to the top wells, the over-
all PMN migration was markedly augmented yielding, in essence,
a doubling effect as compared to 10μMAc2-26 in the bottomwell
alone (Figure 2A).Of interest, the chemotactic response elicited by
1 nMFMLPwas abrogated by adding a higher concentration of the
tri-peptide in the top well (Figure 2B). Finally, when peptide Ac2-
26 was tested in the topwell only, it did not alter the extent of PMN
migration above control responses, except for the 30-μM con-
centration that produced a remarkable neutrophil mobilization
(Figure 2C).
The concentrations of peptide Ac2-26 used in the experiments
are congruent with its apparent binding afﬁnities for human
FPR1 and FPR2/ALX (Walther et al., 2000; Perretti et al., 2002;
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FIGURE 4 | Peptide Ac2-26 induced PMN migration relies primarily on the
ERK signaling pathway. Neutrophils were pre-incubated for 15min at 37˚C
with either (A) PD98059 (ERK inhibitor; 3–30μM), (B) SB203580 (p38
inhibitor; 3–30μM), or (C) SP600125 (JNK inhibitor; 3–30μM) prior to loading
on to a 96 well ChemoTx™ plate in the presence of PBS or peptide Ac2-26
(3–30μM). Chemotaxis was evaluated after a 90-min incubation at 37˚C and
5% CO2. Results are ±SEM from three distinct cell preparations [*P <0.05,
**P <0.01 vs. stimulus alone (dose 0 group)].
Hayhoe et al., 2006). Next, we tested if FPR1 or FPR2/ALX was
responsible for the observed effect, using again 10μM peptide
Ac2-26 to induce human PMN migration. To this end, we used
speciﬁc antibodies against either of the human receptors. Here
the cells were incubated with 10μg/ml (ﬁnal concentration) of
either antibody. Blockade of either formyl peptide receptor was
able to abrogate the chemotactic effect elicited by the Ac2-26
(Figure 3A).
Peptide Ac2-26 engagement of human FPR1 and FPR2/ALX
has been shown to activate the MAPK signaling in an uneven
way, with phosphorylation of ERK but not JNK or p38 (Walther
et al., 2000; Ernst et al., 2004; Hayhoe et al., 2006). Thus, we next
evaluated whether this observation also held true in our exper-
imental conditions showing that incubation of freshly prepared
PMN with Ac2-26 led to ERK phosphorylation, an effect that
could be effectively blocked upon incubation with an ERK speciﬁc
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FIGURE 5 | Peptide Ac2-26 induced human monocytes chemokinesis.
Monocytes were isolated from peripheral blood of healthy volunteers as
indicated in the Section “Materials and Methods” and resuspended at
4×106 cells/ml. (A) Chemotaxis toward peptide Ac2-26 (1–30μM) was
evaluated after a 90-min incubation at 37˚C and 5% CO2. FMLP (1 nM) was
used as positive control. (B) Chemokinesis induced by peptide Ac2-26 was
assessed by incubating the cells with the peptide prior to loading on to the
top well of the ChemoTx™ plate, the number of migrated cells to the
bottom chamber was evaluated after 90min incubation at 37˚C and 5%
CO2. Results are ±SEM of three to four distinct monocyte preparations.
(*P <0.05, **P <0.01 vs. PBS group).
inhibitor (Figure 3B). We next assessed the whether this pathway
was also involved inmediating the chemokinetic effects exerted by
the Ac2-26 peptide. Here we treated freshly prepared neutrophils
with selective pharmacological inhibitors over an extended con-
centration range in order to account for any unspeciﬁc effects
of the inhibitors. Pre-treatment of neutrophils with the ERK
inhibitor, compound PD98059, abolished the cellular response to
peptide Ac2-26, even at the lowest concentration tested of 3μM
(Figure 4A). Intermediate effects were achieved with the p38
inhibitor which was mildly effective at concentrations of 3 and
10μM, yet it only signiﬁcantly attenuated peptide Ac2-26 medi-
ated effects at the highest concentration of 30μM (Figure 4B).
On the other hand pre-treatment of PMN with the JNK inhibitor,
did not have any inﬂuence on the extent of PMN migration
(Figure 4C).
We next extended our observations to another cell type that
is also important in the regulation of the inﬂammatory response,
the monocyte. Here we tested whether peptide Ac2-26 elicited
chemotactic/chemokinetic responses in this cell type, using a con-
centration range of 1–30μM and adding peptide Ac2-26 either
to the bottom wells of the chemotactic plates, or in the top wells.
As seen in Figure 5, addition of the peptide to either the top or
bottom compartment of the chemotaxis plate elicited a marked
response as measured by number of cells mobilized to the bot-
tom well. We observed an increment of ∼10-fold over controls
when either the chemotactic (Figure 5A-addition of the peptide
to the bottom well) or the chemokinetic (Figure 5B-addition of
the peptide to the top well) effects were tested.
DISCUSSION
We demonstrate here that the AnxA1-derived peptide Ac2-26
exerts chemokinetic, rather than chemotactic, effects on human
PMN by acting through either FPR1 or FPR2/ALX and engaging
primarily the ERK signaling pathway.
The seminal work of Gerke’s lab over a decade ago indicated
that peptides derived from the AnxA1 N-terminal could activate
human PMN by engaging the FMLP receptor and in this man-
ner attenuate cell responses such as trans-endothelial migration
(Walther et al., 2000). For a long time peptide Ac2-26 has been
used as an AnxA1 surrogate in view of its ability to replicate the
anti-inﬂammatory (Perretti and Dalli, 2009) and pro-resolving
properties (Maderna et al., 2005, 2010; Scannell et al., 2007) of the
native protein. Therefore, clariﬁcation of the receptor mechanism
engaged by peptide Ac2-26 is of importance as it may have bearing
on the pharmacological exploitation of this line of research for the
development of novel anti-inﬂammatory therapeutics.
The model that emerges is that peptide Ac2-26 can activate all
three human formyl peptide receptors, promoting calcium ﬂuxes,
and cell locomotion (Ernst et al., 2004). Such an effect may be part
of a reparatory process as demonstrated with intestinal epithelial
cells (Babbin et al., 2006) where addition of the peptide engaged
FPRs to activate the cytoskeletalmachinery favoring cellmigration
and repair of the epithelial monolayer. It was therefore surprising
when we conducted binding studies and demonstrated that whilst
full-length AnxA1 bound, and activated, the human FPR2/ALX,
this protein was unable to bind human FPR1 (Hayhoe et al.,
2006). In the same study we conﬁrmed the activation of mitogen-
activated phosphate kinases as an early post-receptor event, with
phosphorylation of ERK but not p38 or JNK, at least within the
time frame of our analyses (30min). It is now clear that in human
monocytes peptide Ac2-26 can activate the JAK/STAT/SOCS sig-
naling requiring ≥60min incubation (Pupjalis et al., 2011). How
canwe explain this disparate receptor engagement betweenAnxA1
and its N-terminal pharmacophore?
One reason behind this dichotomy of behavior could be that
AnxA1 exerts its inhibitory role in the inﬂamed vasculature exclu-
sively through FPR2/ALX, whilst the peptide – which might be
generated at the site of inﬂammation or tissue damage – could
exert chemokinetics or chemoattractant properties via FPR1. We
discussed earlier the generation of N-terminal derived peptides
from AnxA1 in the inﬂammatory exudates by the action of serine
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proteases and other proteolytic activities. In particular, PMN-
derived elastase and proteinase 3 have been advocated as pivotal
enzymes that could truncate the N-terminal region of AnxA1,
which is exposed following calcium binding to the protein (Gerke
and Moss, 2002; Gerke et al., 2005), leading to the release of bio-
logically active peptides. Formation or release of AnxA1-derived
peptides in an inﬂammatory exudate could contribute to resolu-
tion (Perretti andD’Acquisto, 2009) by promoting phagocytosis of
apoptotic PMN by macrophages (Scannell et al., 2007; Maderna
et al., 2010) and dampening inﬂammatory monocyte activation
(Pupjalis et al., 2011). We propose that the data presented here,
would argue for another pro-resolving property of peptide Ac2-
26; the removal of immune cells (PMN and monocytes) from the
site of inﬂammation favoring their exit back into the blood stream
or through the lymphatic circulation and thus promoting tissue
restoration and regain of its pre-inﬂammatory status. If conﬁrmed
in in vivo settings, this biological property of peptideAc2-26would
explain: (i) the apparent discrepancy between AnxA1 and peptide
Ac2-26 binding to human FPR1 and FPR2/ALX and (ii) the need
for generating these short peptides, whereby AnxA1 would act
as a pro-drug. In this respect recent observations made using a
super-AnxA1, resistant to serine protease cleavage, would seem to
argue against the second hypothesis, since this protein displayed
higher anti-inﬂammatory activity then native AnxA1 (Pederzoli-
Ribeil et al., 2010). However, here one needs to make a distinction
between the anti-inﬂammatory properties exerted by AnxA1 (and
super-AnxA1) in the vasculature and/or in the initial phases of
acute inﬂammation, and those that may be operative during the
onset of resolution, especially at the level of the exudate/tissue site,
where these peptides could be generated.
Walther et al. (2000) reported that ∼2 nM circulating AnxA1
can be measured in normal plasma that could augment by 10- to
100-fold in inﬂammatory settings, yielding concentration that can
activate FPR2/ALX (Perretti et al., 2002; Hayhoe et al., 2006). At
very high concentrations, (100–500μM), likely not physiological,
peptide Ac2-26 activates human PMN with production of reac-
tive oxygen species (Walther et al., 2000) whilst inhibitory effects
are predominant within the 10-μM range (Perretti et al., 1995;
Walther et al., 2000). Therefore in our chemotaxis experiments,we
selected concentrations of peptideAc2-26 in the 1- to 30-μMrange
since we deem that concentrations higher that these would be of
little biological signiﬁcance. This especially in consideration of the
fact that the molar ratio AnxA1:peptide Ac2-26 is 1:1, therefore it
is really impossible to envisage pathophysiological settings where
AnxA1 concentrations ≥30μM could be reached.
Peptide Ac2-26 promoted a clear chemokinetic response in
human PMN being, in this way, clearly distinguishable from
FMLP – which produced the expected chemotactic effect (Ye et al.,
2009) hence abolished when the chemical gradient was disrupted.
In line with our initial data on early signaling responses (Hayhoe
et al., 2006), peptide Ac2-26 induced PMN migration was highly
reliant on ERK phosphorylation but not p38 or JNK phosphory-
lation. We reason that the mild effect of the p38 inhibitor, though
signiﬁcant, was solely detected at 30μM concentration alluding
to a possible non-selective response since at concentrations above
10μMthis inhibitor has been shown to also inhibit ERKphospho-
rylation (Lian et al., 1999). Conversely, the ERK speciﬁc inhibitor
markedly affected peptide Ac2-26 elicited PMN migration even
at the 3-μM concentration. The JNK inhibitor acted as negative
control, since it was unable to modulate this cellular response to
peptide Ac2-26 to any appreciable extent, at any of the concen-
tration tested, in line with previous observations (Walther et al.,
2000; Ernst et al., 2004; Hayhoe et al., 2006).
Finally, the issue of the receptor engaged by peptide Ac2-26 in
these experimental settings was addressed. Human PMN express
FPR1 and FPR2/ALX but not FPR3, which is more relevant to
macrophages anddendritic cells (Ye et al., 2009).Neutralizing anti-
bodies to FPR1 (Yazid et al., 2010) or FPR2/ALX (Hayhoe et al.,
2006) abrogated the cellular response to peptide Ac2-26. This is
reminiscent of the data produced in humanPMNunder ﬂowupon
incubation with cromones, though in that study each antibody
produced a partial effect and the combination gave total abroga-
tion (Yazid et al., 2010). In the current experiments peptideAc2-26
could engage either FPR1 or FPR2/ALX to promote PMN migra-
tion and each receptor seemed sufﬁcient to govern this biological
response. There are no doubts that human FPR1 is a chemotac-
tic receptor and the same applies to human FPR2/ALX (Le et al.,
2005).Our data suggests that simultaneous functional activation is
important in eliciting the observed responses, an observation that
favors a mechanism involving cross-talk between the two recep-
tors, potentially resulting from heterodimerization, upon peptide
Ac2-26 application. Future studies will clarify the potential mol-
ecular interlink between FPR1 and FPR2/ALX that these results
indicate. It is noteworthy however that peptide Ac2-26 can bind
and activate FPR1 and FPR2/ALX with similar afﬁnities (Ernst
et al., 2004; Hayhoe et al., 2006).
In conclusion, we provide in vitro evidence that peptide Ac2-
26 can promote locomotion of human primary cells, PMN, and
monocytes. Such an effect is at least in part is due to a chemoki-
netic rather than chemotactic effect elicited by this peptide. This
suggests that generation of AnxA1 N-terminal derived peptides
during the resolution phase of the inﬂammatory response may
play an important role in expediting the removal of blood-borne
cells from the tissue. This in turn would favor the restoration of
homeostasis. As often the case, these novel results incite new ques-
tions that must be addressed in future studies, both in terms of
in vivo relevance as well as in the remit of molecular pharma-
cology, hence the potential modulation of FPR1 and FPR2/ALX
localization upon peptide Ac2-26 application.
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